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Mood disorders (bipolar disorder and major depressive disorder) are highly prevalent, 
and are associated with increased morbidity and mortality. Although treatment of 
depression has advanced, current medications do not meet expectations – only one-
third of patients diagnosed with major depression respond to first level treatment. 
Likewise, polypharmacy is a rule rather than an exception for treatment of bipolar 
disorder ± even lithium, closest to the definition of an ideal mood stabilizer aside from 
its side-effects, has limited success as a monotherapy. It appears that the monoamine 
theory, solely, cannot explain all features of mood disorders, and accordingly, current 
antidepressants targeting monoamine systems are efficient in only a subgroup 
of patients. Novel treatment options are urgently needed. To improve treatment, 
pathoetiology of mood disorders should be elucidated. Understanding pathoetiology 
–in contrast to serendipitous drug discoveries– would enable us to design disorder-
specific drugs and optimize treatment by measuring target engagement.
Relevance
Converging evidence has moved the scientific community to view inflammation 
as a key process that might improve understanding of the pathoetiology of mood 
disorders. Insight into the aberrant immune functioning as a complementary 
mechanism underlying mood disorders can deliver important prognostic information 
to personalize and optimize treatment. From a general perspective, this thesis seeks to 
deliver the next step in this translational aim. 
The findings add important and potentially transformative data to explain the 
relationship between inflammation and mood disorders. To date, inflammation 
in the acute phase of mood disorders (e.g. mania, depression) has been widely 
acknowledged. However, few studies, usually not taking into account the effect 
of medication on immune markers, have examined whether the aberrant immune 
functioning in bipolar disorder resolves during euthymia. This thesis, examining the 
circulatory immune profile of medication-free euthymic bipolar patients and the role 
of immune modulation as a mechanism of action of lithium, has therefore filled an 
important gap in the scientific field. In combination with recent evidence, this suggest 
that inflammatory state likely resolves in euthymic period of bipolar disorder, and 
that the immune-balancing effects of lithium, along with several other postulated 
mechanisms, may be essential for its long-term mood stabilizing effects.
This thesis also provides important evidence towards the role of immune-
related pathways (immune mediated tryptophan catabolism) in the mechanism of 
action of ECT, which has thus far received little attention. Current knowledge about 
antidepressant effects of infliximab (an anti-inflammatory drug) in Crohn’s Disease 
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is extended, thereby facilitating the concept of anti-inflammatory treatment of mood 
disorders. Recent data suggest that prenatal and perinatal complications impact on 
the maternal immune activation and microglial activity, and this work was further 
extended with a study investigating whether hypoxia-related genes moderate the 
impact of obstetric complications on expression of psychopathology. The findings 
further support the idea of gene X environment interaction, whereby hypoxia-response 
genes operate in synergy with obstetric complications to influence the expression of 
mental ill health in general in adulthood.
The exploration of inflammation and the pathoetiology of mood disorders 
is an active area of investigation in the scientific community. This thesis offers 
some insight into indices of inflammation underlying mood disorders, and delivers 
translational information about the role of inflammation in treatment of mood 
disorders. Although further longitudinal studies are reTuired, these findings, from 
a broad perspective, suggest that immune stratification of patients with mood 
disorders ±such as, from the most basic perspective, categorizing patients into low 
and high inflammation groups± might be helpful in predicting treatment response 
and remission. In addition, identifying subtypes, such as ³inflamed´ depression, 
may open up new avenues leading to individually tailored treatment with better 
outcomes. 
Social and economic burden of mood disorders include disability, decreased work 
productivity, and increased health services utilization. A more effective treatment 
would not only decrease mood symptoms, but also improve quality of life and restore 
functioning. Although treatment of mood disorders has improved substantially, the rate 
of complete remission is low –indicating a need for treatment with novel mechanisms 
of action. There is some evidence to suggest that anti-inflammatory drugs (i.e. aspirin, 
celecoxib, omega-3 fatty acids, and minocycline) are beneficial as an augmentation 
treatment for mood disorders. However, study results are inconsistent. This is likely 
due to collective analysis of immunologically heterogeneous samples. Therefore, 
immune profiling may be essential to define patients who may benefit more from 
adjuvant anti-inflammatory treatment.
Although reported findings can be considered as another brick in the wall, even 
the Great Wall of China was built laying one brick at a time. Studies investigating 
immune hypotheses have thus far provided substantial evidence suggesting that 
measurement of immune alterations may serve as biomarkers in mood disorders. 
However, we are still far from translating these findings to be applied in clinical 
practice because further prospective, controlled investigations are needed. Studies 
should aim to investigate large samples and carefully take into account various 
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confounders that can easily distort results, such as medication effect demonstrated 
in this thesis. 
Target groups
Considering that the impact of mood disorders spread across the society, with 
various effects, from patients to family members and from organizations to taxpayers, 
a wide range of people can benefit from optimization of diagnosis and treatment of 
mood disorders, either directly or indirectly. Therefore, the findings of this thesis 
extending the knowledge to pave the way to advanced diagnostic panels and better 
treatment options may be of use to a broader population. In psychiatric practice, 
healthcare professionals usually struggle to identify future treatment-resistant cases, 
and this results in inadequate treatment initially, followed by several drug trials until 
optimal treatment is achieved. Not to mention that extended duration of inadequate 
treatment is associated with disability, but it also poses a great risk to patients by 
increasing the likelihood of suicide. Unfortunately, there exists no biomarker that 
can help healthcare professionals to predict response or remission in patients with 
mood disorders. Given that, healthcare professionals can certainly benefit from 
tracking immune markers to develop personalized treatment strategies, which 
eventually reduce duration of inadequate treatment. This decrease of time lost by 
inadeTuate treatment, will subseTuently decrease service utilization and costs. These 
are also important objectives that policy makers seek to achieve for improving cost-
effectiveness. However, it would be an overstatement to claim that immune markers 
are ready for use in everyday clinical practice. Circulatory immune markers are 
prone to the impact of confounding factors, unreliable at times, and still expensive 
to measure with available methods. Rapidly advancing measurement technologies 
delivered assays that allow measurement of multiple immune markers using a single 
kit and, therefore, led to a dramatic reduction in costs. This downward trend in costs 
will accelerate even more in the forthcoming years.
Obviously, the present findings support the development of anti-inflammatory 
therapy for mood disorders. There is already some evidence that augmentation 
treatment with potent anti-inflammatory therapies might increase response rates 
and reduce time to response, particularly in treatment-refractory cases. However, 
side effects that include increased risk of serious infections limit their use. 
Hopefully, the next generation of anti-inflammatory drugs, targeting specific 
molecular pathways, with fewer side effects may add to clinicians’ arsenal for 
treatment-resistant cases.
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Innovation
This thesis delivers actionable and reliable information for future studies, and it is 
innovative in several specific ways. First, it used several approaches in a variety of 
samples to delineate putative role of inflammation in pathoetiology of mood disorders. 
Second, it shed light on neglected areas in the literature on psychoneuroimmunology, 
such as the role of immune-related pathways in the mechanism of action of ECT. 
Third, it analyzed data derived from uniTue patient populations, such as unmedicated 
euthymic bipolar patients and euthymic bipolar patients with subthreshold symptoms. 
